CN1185812A - 表达胆汁盐刺激脂酶(bssl)的dna分子 - Google Patents
表达胆汁盐刺激脂酶(bssl)的dna分子 Download PDFInfo
- Publication number
- CN1185812A CN1185812A CN96194083A CN96194083A CN1185812A CN 1185812 A CN1185812 A CN 1185812A CN 96194083 A CN96194083 A CN 96194083A CN 96194083 A CN96194083 A CN 96194083A CN 1185812 A CN1185812 A CN 1185812A
- Authority
- CN
- China
- Prior art keywords
- pro
- gly
- ala
- thr
- val
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100035687 Bile salt-activated lipase Human genes 0.000 title claims abstract description 86
- 108020004414 DNA Proteins 0.000 title claims abstract description 29
- 108010087173 bile salt-stimulated lipase Proteins 0.000 title abstract description 82
- 102000053602 DNA Human genes 0.000 title abstract 3
- 241000235058 Komagataella pastoris Species 0.000 claims abstract description 39
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 37
- 229920001184 polypeptide Polymers 0.000 claims abstract description 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 26
- 108010025188 Alcohol oxidase Proteins 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 18
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 15
- 108091026890 Coding region Proteins 0.000 claims abstract description 5
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 235000001014 amino acid Nutrition 0.000 claims description 14
- 101100244726 Pisum sativum PPF-1 gene Proteins 0.000 claims description 12
- 239000013604 expression vector Substances 0.000 claims description 11
- 230000004071 biological effect Effects 0.000 claims description 10
- 241000235648 Pichia Species 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 101001076706 Saccharomyces cerevisiae Invertase 1 Proteins 0.000 claims description 3
- 101001053411 Saccharomyces cerevisiae Invertase 3 Proteins 0.000 claims description 3
- 101001053412 Saccharomyces cerevisiae Invertase 4 Proteins 0.000 claims description 3
- 101001053409 Saccharomyces cerevisiae Invertase 5 Proteins 0.000 claims description 3
- 101001053400 Saccharomyces cerevisiae Invertase 7 Proteins 0.000 claims description 3
- 239000013600 plasmid vector Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 101710130200 Bile salt-activated lipase Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 25
- 238000004113 cell culture Methods 0.000 abstract description 4
- 230000028327 secretion Effects 0.000 abstract description 4
- 239000013598 vector Substances 0.000 abstract description 3
- 108700026244 Open Reading Frames Proteins 0.000 abstract description 2
- 101000715643 Homo sapiens Bile salt-activated lipase Proteins 0.000 abstract 1
- 102000052905 human CEL Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 235000018102 proteins Nutrition 0.000 description 29
- 102000004169 proteins and genes Human genes 0.000 description 29
- 230000000694 effects Effects 0.000 description 25
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 24
- 239000012228 culture supernatant Substances 0.000 description 23
- 102220369445 c.668T>C Human genes 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 239000002299 complementary DNA Substances 0.000 description 14
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 14
- 239000012634 fragment Substances 0.000 description 13
- 238000001262 western blot Methods 0.000 description 13
- 102220023258 rs387907548 Human genes 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 230000001939 inductive effect Effects 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 108090001060 Lipase Proteins 0.000 description 10
- 102000004882 Lipase Human genes 0.000 description 10
- 239000004367 Lipase Substances 0.000 description 10
- 235000019421 lipase Nutrition 0.000 description 10
- 230000029087 digestion Effects 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 8
- 102220369447 c.1352G>A Human genes 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 108010050848 glycylleucine Proteins 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 101150005709 ARG4 gene Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008521 reorganization Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 101150069554 HIS4 gene Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 210000005075 mammary gland Anatomy 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 101100004044 Vigna radiata var. radiata AUX22B gene Proteins 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000011073 invertase Nutrition 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- PMQXMXAASGFUDX-SRVKXCTJSA-N Ala-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CCCCN PMQXMXAASGFUDX-SRVKXCTJSA-N 0.000 description 2
- 102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 2
- 108010051152 Carboxylesterase Proteins 0.000 description 2
- 102000013392 Carboxylesterase Human genes 0.000 description 2
- 101150015280 Cel gene Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 description 2
- JRDYDYXZKFNNRQ-XPUUQOCRSA-N Gly-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN JRDYDYXZKFNNRQ-XPUUQOCRSA-N 0.000 description 2
- LCNXZQROPKFGQK-WHFBIAKZSA-N Gly-Asp-Ser Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O LCNXZQROPKFGQK-WHFBIAKZSA-N 0.000 description 2
- KAJAOGBVWCYGHZ-JTQLQIEISA-N Gly-Gly-Phe Chemical compound [NH3+]CC(=O)NCC(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 KAJAOGBVWCYGHZ-JTQLQIEISA-N 0.000 description 2
- UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 description 2
- 101000780443 Homo sapiens Alcohol dehydrogenase 1A Proteins 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- HVAUKHLDSDDROB-KKUMJFAQSA-N Lys-Lys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HVAUKHLDSDDROB-KKUMJFAQSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AUJWXNGCAQWLEI-KBPBESRZSA-N Phe-Lys-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O AUJWXNGCAQWLEI-KBPBESRZSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- LVFZXRQQQDTBQH-IRIUXVKKSA-N Tyr-Thr-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O LVFZXRQQQDTBQH-IRIUXVKKSA-N 0.000 description 2
- XLDYBRXERHITNH-QSFUFRPTSA-N Val-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)C(C)C XLDYBRXERHITNH-QSFUFRPTSA-N 0.000 description 2
- VVZDBPBZHLQPPB-XVKPBYJWSA-N Val-Glu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O VVZDBPBZHLQPPB-XVKPBYJWSA-N 0.000 description 2
- 108010058834 acylcarnitine hydrolase Proteins 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 108010006664 gamma-glutamyl-glycyl-glycine Proteins 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 235000021243 milk fat Nutrition 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- YFKWIIRWHGKSQQ-WFBYXXMGSA-N Cys-Trp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CS)N YFKWIIRWHGKSQQ-WFBYXXMGSA-N 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 101001018100 Homo sapiens Lysozyme C Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- LOLUPZNNADDTAA-AVGNSLFASA-N Leu-Gln-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LOLUPZNNADDTAA-AVGNSLFASA-N 0.000 description 1
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 1
- FYRUJIJAUPHUNB-IUCAKERBSA-N Met-Gly-Arg Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N FYRUJIJAUPHUNB-IUCAKERBSA-N 0.000 description 1
- XDGFFEZAZHRZFR-RHYQMDGZSA-N Met-Leu-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XDGFFEZAZHRZFR-RHYQMDGZSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101150051118 PTM1 gene Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 101150014136 SUC2 gene Proteins 0.000 description 1
- AZSHAZJLOZQYAY-FXQIFTODSA-N Val-Ala-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O AZSHAZJLOZQYAY-FXQIFTODSA-N 0.000 description 1
- UMPVMAYCLYMYGA-ONGXEEELSA-N Val-Leu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O UMPVMAYCLYMYGA-ONGXEEELSA-N 0.000 description 1
- BGTDGENDNWGMDQ-KJEVXHAQSA-N Val-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N)O BGTDGENDNWGMDQ-KJEVXHAQSA-N 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 101150083105 his-44 gene Proteins 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000021244 human milk protein Nutrition 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- XUWPJKDMEZSVTP-LTYMHZPRSA-N kalafungina Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1[C@@H](C)O[C@H]1[C@@H]2OC(=O)C1 XUWPJKDMEZSVTP-LTYMHZPRSA-N 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 108010021711 pertactin Proteins 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
- C12N1/18—Baker's yeast; Brewer's yeast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Botany (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
本发明涉及在甲基营养酵母巴斯德毕赤酵母中表达胆汁盐刺激脂酶的方法中使用的DNA分子,重组载体和细胞培养物。DNA分子包含:(a)编码为人BSSL或其生物活性变异体的多肽的区域;(b)与所述多肽编码区相连的,编码能操纵所述多肽从用所述DNA分子转化的巴斯德毕赤酵母细胞分泌的信号肽的区域;(c)可操作性地与(a)和(b)中定义的所述编码区相连的巴斯德毕赤酵母的甲醇氧化酶启动子或功能等价的启动子。
Description
技术领域
本发明涉及用于在甲基营养酶母巴斯德毕赤酵母中表达胆汁盐刺激脂酶(BSSL)的方法中的DNA分子,重组载体和细胞培养物。背景技术
胆汁盐刺激脂酶(BSSL;EC3.1.1.1)(综述见Wang和Hartsuck,1993)提供大部分人乳汁脂裂解活性。该脂酶的一个特点是需要初级胆汁盐来提供抗乳化的长链三酰基甘油的活性。至今为止,仅在来自人,大猩猩,猫和狗的奶中发现了BSSL(Hernell等,1989)。
BSSL在母乳喂养婴儿的肠中的乳汁脂肪的消化中起着关键性的作用(Fredrikzon等,1978)。BSSL在人分泌乳汁的乳腺中合成并随乳汁一起分泌(Bickberg等,1987)。它占全部乳汁蛋白的约1%(Blckberg和Hernell,1981)。
已认为BSSL是脂肪吸收和随后的生长中主要速率限制因素,尤其是未成年的在其自身合成BSSL有缺陷的婴儿。补充纯化酶的办法明显改善了这些婴儿的消化和生长(U.S.4,944,944;Oklahoma医学研究基金)。这在制备含有高百分比的三甘油酯和基于植物或非人类乳汁蛋白来源的婴儿配制剂的生产中具有临床学重要性,因为用这些配制剂喂养的婴儿在没有外加的BSSL时不能消化脂肪。
已鉴定出乳汁BSSL和胰羧酸酯水解酶(CEH)的cDNA结构(Baba等,1991;Hui和Kissel,1991;Nilsson等,1991,Reue等,1991),并已作出结论,即乳汁酶和胰酶为相同基因,CEL基因的产物。CEL基因的cDNA序列(SEQ ID NO:1)公开在US5,200,183(Oklahoma医学研究基金);WO 91/18293(Aktiebolaget Astra);Nilsson等(1990);和Baba等(1991)中。推测的BSSL蛋白的氨基酸序列,包括23个氨基酸的信号肽,示于序列表中的SEQ ID NO:2,同时722个氨基酸的天然蛋白质的序列示于SEQ ID NO:3。
蛋白质的C末端区含有各为11个氨基酸残基的16个重复单元,接着是11个氨基酸的保守区段。天然蛋白质为高度糖基化,并已报道了宽范围的观察到的分子量。这可通过糖基化的变化程度来解释(Abouakil等,1988)。该的N末端的一半与乙酰胆碱酯酶和一些其它的酯酶同源(Nilsson等,1990)。
可通过在适宜宿主,例如大肠杆菌,啤酒糖酵母或哺乳动物细胞系中的表达来制备重组BSSL。为了扩大这种制备费用为商业上可接受的BSSL表达体系,可设想使用异源表达体系。如上面所提到的,人BSSL在C末端具有11个氨基酸的16个重复单元。为了确定这一重复区域的生物重要性,已构建了部分缺少或全部缺少重复区的人BSSL各种突变体(Hansson等,1993)。变异体BSSL-C(SEQ ID NO:4),例如缺失氨基酸残基536-568以及残基591-711。使用哺乳动物细胞至C127宿主和牛乳头状瘤病毒表达载体的表达研究表明各种变异体可以活性形式表达(Hansson等,1993)。从表达研究中还可总结出人BSSL中的富含脯氨酸的重复对于BSSL的催化活性或胆汁盐活性是非必需的。然而,在哺乳动物表达体系中制备BSSL或其突变体对于常规治疗用途来说可能太昂贵。
与使用原核体系相比,真核体系,例如酵母对于制备由重组DNA编码的一些多肽可提供明显的优点。例如,酵母可通常比细菌生长的细胞密度高,并可证实能糖基化表达的多肽,而这种糖基化对于生物活性是重要的。然而,使用啤酒糖酵母作为宿主器官通常导致不良的表达水平和重组蛋白的不良分泌(Cregg等,1987)。啤酒糖酵母中的异源蛋白质的最高水平为占全部细胞蛋白质5%的范围(Kingsman等,1985)。使用啤酒糖酵母作为宿主的另一个缺点是重组蛋白质可能被过度糖基化,这样可能影响糖基化的哺乳动物蛋白质的活性。
巴斯德毕赤酵母是以甲醇作为唯一碳源和能源而生长的甲基营养酵母,因为它包含高度调控的甲醇利用途径(Ellis等,1985)。毕赤酵母还可适合于有效的高细胞密度发酵技术。因此,重组DNA技术和有效的酵母转化的方法使得有可能开发巴斯德毕赤酵母作为使用基于甲醇氧化酶启动子的表达体系高产量地表达异源蛋白质的宿主(Cregg等,1987)。
现有技术业已知使用巴斯德毕赤酵母作为用于表达例如下面的异源蛋白质的宿主:人肿瘤坏死因子(EP-A-0263311);博德特氏杆菌属pertactin抗原(WO 91/15571);乙型肝炎表面抗原(Cregg等,1987);人溶菌酶蛋白(WO 92/04441);抑蛋白酶肽(WO 92/01048)。然而,活性,可溶及分泌形式的异源蛋白质的成功表达取决于各种因素,例如信号肽的正确选择,信号肽和成熟蛋白质之间的融合连接的适宜构建,生长条件等。发明目的
本发明的目的是克服前面体系的缺陷,提供一种高效且可与在其它生物中的制备相比,或优于它的制备人BSSL的方法。该目的已通过提供在巴斯德毕赤酵母细胞中表达BSSL的方法而实现。
通过本发明因而表明人BSSL和突异体BSSL-C可从巴斯德毕赤酵母中以活性形式分泌。天然信号肽以及来自啤酒糖酵母转化酶蛋白质的异源信号肽被用于将成熟蛋白质以具活性的,适当的加工形式转移到培养基中。发明描述
第一方面,本发明提供了DNA分子,它包含:(a)编码人BSSL或其生物活性变异体的多肽的区域;(b)与所述多肽编码区的5′末端相连的,编码能指导所述多肽分泌的信号肽,所述多肽来自经所述DNA分子转化的巴斯德毕赤酵母细胞;(c)可操作性地与(a)和(b)中定义的所述编码区相连的巴斯德毕赤酵母的甲醇氧化酶启动子或功能相同的启动子。
术语BSSL的“生物活性变异体”应理解为具有BSSL活性并包含序列表中SEQ ID NO:3所示氨基酸序列的一部分的多肽。本文中术语“具有BSSL活性的多肽”应理解为包含下面性质的多肽:(a)适宜于口服施用;(b)由特定的胆汁盐活化;和(c)在小肠内含物中起非特异性脂酶的作用,即能水解脂肪而相对与它们的化学结构和物理状态(乳化的,分子团,可溶的)无关。
所述BSSL变异体可例如为包含少于16个重复“单元”的变异体,其中“重复单元”应理解为11个氨基酸的重复单元,由在序列表“SEQID NO:1”的“(ix)特点”标题下的指明为“重复单元”的核苷酸序列编码。尤其是,BSSL变异体可为变异体BSSL-C,其中缺失氨基酸536-568以及591-711(序列表SEQ ID NO:4)。
因此,根据本发明的DNA分子优选为编码BSSL(SEQ ID NO:3)或BSSL-C(SEQ ID NO:4)的DNA分子。
然而,根据本发明的DNA分子不应严格限制为编码具有与序列表中SEQ ID NO:3或4相同的氨基酸序列的多肽的DNA分子。而且本发明包括编码带有修饰,例如取代,小的缺失,插入或倒位的多肽的DNA分子,其中这些多肽仍基本上具有BSSL的生物活性。因此,本发明包括编码上述BSSL变异体的DNA分子以及还包括编码其氨基酸序列与序列表中SEQ3或4所示的氨基酸序列至少90%同源,优选至少95%同源的多肽的DNA分子。
上面提到的信号肽可为与具有序列表中SEQ ID NO:2的氨基酸-20至-1所示的氨基酸序列的肽相同或基本相似的肽。另一方面,它可为包含啤酒糖酵母转化酶信号肽。
另一方面,本发明提供包含上面定义的DNA分子的载体。优选地,该载体为可复制表达载体,它带有并且能介导毕赤酵母属细胞中的编码人BSSL或其生物活性变异体的DNA序列的表达。该载体可例如为质粒载体pARC 5771(NCIMB 40721),pARC 5799(NCIMB 40723)或pARC 5797(NCIMB 40722)。
另一方面,本发明提供了包括用DNA分子或上面定义的载体转化的毕赤酵母属细胞的宿主细胞培养物。优选地,该宿主细胞为例如PPF-1或GS115菌株的巴斯德毕赤酵母细胞,所述细胞培养物可例如为培养物PPF-1[pARC 5771](NCIMB 40721),或GS115[pARC 5799](NCIMB40723)或GS115[pARC 5797](NCIMB 40722)。
另一方面,本发明提供一种制备人BSSL或其生物活性变异体的多肽的方法,它包括在使所述多肽被分泌至培养基中的条件下,培养根据本发明的宿主细胞,并从培养基中回收所述多肽。本发明实施例实施例1:巴斯德毕赤酵母PPF-1中的BSSL的表达1.1.pARC 0770的构建
将编码BSSL蛋白质,包括天然信号肽(下面称为NSP)的cDNA序列以EcoRI-SacI片段克隆至pTZ19R中(Pharmacia)。两步完成将NSP-BSSL cDNA克隆至啤酒糖酵母表达载体pSCW 231中(从L.Prakash教授获得,Rochester大学,NY,USA),该表达载体为低拷贝数的酵母表达载体,其中表达且受组成型ADH1启动子控制。开始将NSP-BSSL cDNA以来自pTZ19R-SP-BSSL的EcoRI-SphI片段克隆至pYES 2.0中(Invitrogen,USA)。通过产生EcoRI/Ncol(89)融合和重新产生EcoRI位点除去在信号肽编码序列开始处的EcoRI和NcoI之间的过剩的89个碱基对产生的克隆pARC 0770含有起初编码在NcoI位点,并紧接框内带有剩余NSP-BSSL序列的重新产生的EcoRI位点的ATG密码子。1.2.pARC 5771质粒的构建
为了构建表达BSSL的适宜的表达载体,将编码BSSL蛋白质和其天然信号肽的cDNA片段用巴斯德毕赤酵母表达载体pDM 148克隆。载体pDM 148(从Dr.S.Subramani,UCSD)按如下构建:甲醇氧化酶(MOX1)基因的上游非翻译区(5′-UTR)和下游非翻译区(3′-UTR)通过PCR而被分离,并串联放入大肠杆菌载体pSK+(可从Stratagene,USA购得)的多克隆序列(MCS)中。
为了适当地选择预计的巴斯德毕赤酵母转化体,将编码啤酒糖酵母ARG4基因和其本身启动子序列的DNA序列插入到pSK-中的5′-和3′-UTR之间。产生的构建物pDM 148具有下面特征:在pSK-的MCS区中,MOX的5′-UTR,啤酒糖酵母ARG4基因组序列和MOX的3′-UTR被克隆。在MOX的5′-UTR和ARG4基因组序列之间,一系列单一的限制性位点(SalI,ClaI,EcoRI,PstI,SmaI和BamHI)被定位,其中任何异源蛋白质编码序列在巴斯德毕赤酵母中的MOX启动子的控制下可被克隆用于表达。为了便于将该表达盒整合到巴斯德毕赤酵母染色体中的MOX1基因座中,可通过用NotI限制性酶消化将表达盒从pSK-载体的其余部分中酶切。
在pDM148中克隆的巴斯德毕赤酵母的MOX1的5′-UTR长度约为500bp,而克隆至pDM 148的来自巴斯德毕赤酵母的MOX1的3′-UTR长度为约1000bp。为了在pDM148中MOX1的5′-UTR和啤酒糖酵母ARG4编码序列之间插入NSP-BSSL cDNA序列,通过用EcoRI和BamHII消化从pARC 0770中分离cDNA插入片段(SP-BSSL)(约2.2kb DNA片段),并在pDM 148的EcoRI和BamHII位点之间克隆。
产生的构建物pARC 5771(NCIMB 40721)包含巴斯德毕赤酵母MOX1 5′-UTR,接着是NSP-BSSL编码序列,随后是啤酒糖酵母ARG4基因序列和巴斯德毕赤酵母的MOX1基因的3′-UTR,同时在pSK-的MCS克隆从MOX1的5′-UTR到MOX1的3′-UTR的全部DNA片段。1.3巴斯德毕赤酵母宿主PPF-1中的BSSL的转化
为在巴斯德毕赤酵母宿主PPF-1(his4,Arg4;从PhillipsPetroleum公司获得)表达BSSL,用NotI消化质粒pARC 5771,将全部消化的混合物(10μg的总的DNA)用于转化PPF-1。接下来的转化方法基本上是Cregg等(1987)描述的酵母原生质球方法。在缺乏精氨酸的基本培养基上再生转化体,这样可选择Arg+克隆。取出含有转化体的再生顶部琼脂,在水中均化,在缺乏精氨酸的基本葡萄糖平板上以每板约250个克隆平板接种酵母细胞。接着通过影印培养至最低甲醇平板来鉴定突变克隆。所有转化体的约15%表现为MutS(甲醇缓慢生长)表型。1.4.表达BSSL的转化体的筛选
为了迅速筛选大量的表达脂酶的转化体,研究了一种脂酶平板分析方法。制备这些平板的方法如下:向2%琼脂糖溶液(最终浓度)中加入10×胆酸钠的水溶液至最终浓度为1%。向混合物中加入脂底物trybutine至最终浓度为1%(v/v)。为了支持转化体的生长,对混合物进一步补充0.25%酵母氮基(最终)和0.5%甲醇(最终)。适当混合各组分,并倒入3-5mm厚的平板中。一旦混合物变为固体,将转化体划线至平板上,再将平板在37℃下培养12小时。产生脂酶的克隆在克隆周围显示出清楚的晕圈。在一常规实验中,全部93个转化体中的7个被鉴定为产生BSSL转化体。挑出围绕划线菌落的产生最大晕圈的两个克隆(39和86号)用于进一步鉴别。1.5来自PPF-1[pARC 5771]的BSSL的表达
挑出1.4节描述的两个转化体39和86号,30℃下,在BMGY液体培养基(1%酵母提取液,2%细菌胨,1.34%无氨基酸的酵母氮基,100mM KPO4缓冲液,pH6.0,400μg/l生物素,和2%甘油)中生长24小时直至培养基的A600接近40。沉淀培养物,重新悬浮A600=300的BMMY(在BMGY中用0.5%甲醇代替2%甘油)培养基中。30℃下,将诱导的培养基摇荡培养120小时。在不同的时间点提取培养物上清液通过酶活性分析,SDS-PAGE分析和蛋白质印迹法来分析BSSL的表达。1.6在克隆号38和86的培养物上清液中BSSL酶活性的检测
为了检测1.5节中描述的号39和86的诱导培养物的无细胞培养物上清液中的酶活性,离心培养物,根据Hernell和Olivecrona(1974)描述的方法分析2μl无细胞上清液的BSSL酶活性。如表1所示,在保温96小时后,在两种培养基中发现包含具有最大活性的BNSSL酶活性。1.7.PPF-1:pARC 5771转化体(号39和86)的培养物上清液的蛋白质印迹分析
为了确定号39和86 PPF-1[pARC 5771]转化体的培养物上清液中重组BSSL的存在,如1.5节描述的培养并诱导培养物。在诱导之后不同的时间点提取培养物,并使用抗BSSL多克隆抗体进行蛋白质印迹分析。结果表明在培养物上清液中BSSL以116kDa的带存在。实施例2:毕赤酵母GS115中BSSL的表达2.1.pARC 5799的构建
由于末完全确定5′-MOX UTR和3′-MOX UTR。并且由于pDM148载体缺乏任何其它的监测整合在巴斯德毕赤酵母属染色体中的BSSL的拷贝数的适宜的标记(例如G418抗性基因),因此将天然BSSL的cDNA与其信号肽一起克隆至另一个巴斯德毕赤酵母表达载体pHIL D4中。整合的质粒pHIL D4从Petroleum公司获得。该质粒含有5′-MOX1,约1000bp的醇氧化酶启动子片段和一个EcoRI克隆位点。在EcoRI位点之后它还包含含有醇氧化酶终止序列的约250 bp的3′-MOX1区。“终止”区之后是包含在与宿主GS115的缺损HIS4基因互补的2.8kb片段中的巴斯德毕赤酵母组氨醇脱氢酶基因HIS4(见下文)。含有3′-MOX1 DNA的650bp区在HIS4基因的3′末端融合,它与5′-MOX1区一起对于定点整合是必需的。来自pUC-4K(PL-Biochemicals)的细菌卡那霉素抗性基因在HIS4和HIS4基因的3′处的3′-MOX1区之间的唯一的NaeI位点被插入。
为了将NSP-BSSL编码cDNA片段克隆在pHIL D4的唯一的EcoRI位点上,将具有BamHI-EcoRI酶切位置的双链寡接头与BamHI消化的质粒PARC 5771连接,分离2.2kb EcoRI片段的全部NSP-BSSL编码序列。将该片段克隆在pHIL D-4的EcoRI位点,该正确定向的质粒称为pARC 5799(NCIMB 40723)。2.2.pARC 5799的转化
为了便于整合位于巴斯德毕赤酵母的MOX1的基因组基因座的NSP-BSSL编码序列,根据节1.5描述的方法将质粒pARC 5799用BglII消化,用于巴斯德毕赤酵母菌株GS115(his4)(Phillips Petroleum公司的转化。然而,这种筛选是His原养型。在再生上面琼脂上进行系列稀释平板接种之后,挑出转化体,如节1.4描述的直接检测脂酶平板分析。根据脂酶分析平板上的晕圈的大小挑出两个转化体克隆(号9和21),进一步检测BSSL的表达。发现这些克隆为Mut+。2.3.GS115[pARC 5799]转化体号9和21的培养上清液中的BSSL酶活性的检测。
基本上根据节1.5描述的方法培养GS115[pARC 5799]的两个转化克隆号9和21。如节1.6描述的,在诱导之后的不同时间点分析培养上清的BSSL酶活性。如表1所示,发现两培养上清中均含有BSSL酶活性,并且保温72小时之后的酶活性最高。与PPF-1[pARC 5771]克隆相比,两个克隆均显示出极好的BSSL表达。2.4 GS115[pARC 5799]转化体号9和21的培养上清的SDS-PAGE和蛋白质印迹分析
将如节2.3中描述的在不同时间点收集的培养上清进行SDS-PAGE和蛋白质印迹分析。从SDS-PAGE图谱中,估计诱导培养物的培养上清中存在的全部蛋白质60-75%为BSSL。该蛋白质的分子量为约116kDa蛋白质免迹数据也证实存在于培养上清中的主要蛋白质为BSSL。该蛋白质显然具有与天然BSSL相同的分子量。实施例3:BSSL表达的放大3.1.来自转化克隆GS115[pARC 5799](号21)的BSSL表达的放大
使用23升容量的B.Braun发酵罐。121℃下,将5升含有1%YE,2%胨,1.34YNB和4%w/v甘油的培养基高压灭菌30分钟,在滤器灭菌之后,在接种期间加入生物素(最终浓度为400μg/l。对于接种物,使用接种到含有YNB(67%)加上2%甘油(150ml)的合成培养基上,并在30℃下生长36小时的GS115[pARC 5799](号21)的甘油贮液。发酵条件如下,温度为+30℃;使用3.5N NH4OH和2N HCl维持pH5.0;溶解的氧为空气饱和度的20-40%;聚丙二醇2000被用作消沫剂。
在固定的间隔通过测定600nm的OD来监测生长。24小时A600达到最大值50-60。此时,分批生长期结束,这由增加的溶解氧水平得以说明。
紧接生长期为诱导期。在此期间,加入含12ml/L PTM1盐的甲醇。在起初10-12小时期间,甲醇进料率为6μl/小时,此后每7-8小时以6μl/小时的增加量逐渐增加至最大为36ml/小时。用于pH控制的氨用作氮源。通过使用溶解氧的高峰,每6-8小时检测甲醇的累积,发现在诱导全期期间它是有限的,在甲醇进料86小时期间,600nm的OD从50-60增加至150-170。每隔24小时加入酵母提取物和胨,使得最终浓度分别为0.25%和0.5%。
每24小时间隔取出样品,检测无细胞发酵液中的BSSL酶活性,还将发酵液进行SDS-PAGE和蛋白质印迹分析。3.2.从发酵罐生长培养物GS115[pARC 5799](号21)分泌的BSSL的蛋白质分析
无细胞发酵液中的BSSL酶活性从24小时处的40-70mg/l(天然蛋白质当量)增加到最后86-90小时处的最高200-227.0mg/l(天然蛋白质当量)。无细胞发酵液的SDS-PAGE分析显示出分子量为116kDa的显著的考马斯兰染色的带。通过进行如节1.7所描述的蛋白质印迹证实了这条带对于天然BSSL的同一性。3.3.分泌到GS115[pARC 5799](号21)克隆的培养上清中的重组BSSL的纯化
如节3.1所描述的,在发酵罐中培养和诱导巴斯德毕赤酵母克隆GS115[pARC 5799]。为了纯化重组BSSL,以12,000×g将250ml培养基(诱导90小时)离心30分钟以除去所有颗粒物质。在Amicon装置中,使用10KDa分离膜超过滤无细胞培养上清。在过滤期间,通过重复稀释去除培养上清中的盐和低分子量蛋白质和肽。用于稀释的缓冲液为5mMBarbitol pH7.4。浓缩培养上清后,使用5mM Barbitol,pH7.4和5mMNaCl使截留物重新恢复为250ml,并上样至用相同缓冲液预平衡的Heparin-琼脂糖柱(15ml床体积)。以10ml/小时的流速进行样品上样。上样后,将柱用5mM Barbitol,pH7.4和0.1M NaCl(200μl洗涤缓冲液)直至250nm处的吸光率低于检测水平。用200ml Barbitol缓冲液(5mM,pH7.4)和线性梯度为0.1M-0.7M的NaCl洗脱BSSL收集级分(2.5ml),并通过监测200nm处的吸光率来检测被洗脱蛋白。分析含有蛋白质的级份的BSSL酶活性。用检测纯化的8.0%SDS-PAGE图谱分析适当的级份。3.4.分泌在GS115[pARC 5799]培养上清中的纯化的重组BSSL的鉴定
显示最大BSSL酶活性的级份(如节3.3描述)的SDS-PAGE和蛋白质印迹分析证明重组蛋白质纯度为约90%。通过SDS-PAGE和蛋白质印迹分析证实纯化蛋白质的分子量为约116kDa。当样品在SDS-PAGE分析中过载时,用考马斯亮兰染色可检测到一低分子量蛋白带,这条带在蛋白质印迹中未被检出。将纯化蛋白在自动蛋白质序列分析仪上进行N末端分析。结果表明该蛋白质从天然信号肽经过了恰当的加工,重组蛋白质具有AKLGAVY的N末端序列。纯化的重组蛋白质的比活被发现类似于天然蛋白质。实施例4:巴斯德毕赤酵母GS115中的BSSL表达4.1.pARC 5797的构建
将BSSL突异体BSSL-C的cDNA编码序列在其5′末端与啤酒糖酵母SUC2基因产物(转化酶)的信号肽编码序列融合,同时保持转化酶信号肽的第一个ATG密码子开始的开放读框的完整性。一开始将该融合基因构建物克隆至啤酒糖酵母表达载体pSCW231(pSCW231为低拷贝数酵母表达载体,表达受组成型ADH1启动子控制)的EcoRI和BamHI位点之间以产生表达载体PARC 0788。
通过EcoRI和BamHI消化pARC 0788释放适宜的1.8Kb片段并将该片段亚克隆至用EcoRI和BamHI消化的pDM148中,进一步将融合基因的cDNA亚克隆至巴斯德毕赤酵母表达载体pDM 148中(第1.2中描述的)。在如节2.1描述的方法之后将产生的构建物pARC 5790用BamHI消化,连接物质结构物BamHI-EcoRI-BamHI的双链寡核苷酸接头以产生分离融合基因的cDNA片段所必需的构建物pARC 5796。
最后通过EcoRI消化从pARC 5796释放含有转化酶信号肽/BSSL-C融合基因的1.8kb片段。并克隆至pHIL D4的EcoRI位点。通过对表达的适宜的限制性分析,鉴别出在合适定位上含有插入片段的载体,称为pARC 5797(NCIMB 40722)。4.2.巴斯德毕赤酵母的重组BSSL-C的表达
为了从巴斯德毕赤酵母表达重组BSSL-C,通过如节1.3和2.2描述的方法,用pARC 5797转化巴斯德毕赤酵母宿主GS115。用节1.4和2.2中描述的方法,检测转化体的脂酶产生,构建高脂酶产生活性,用脂酶平板分析检测法挑出-转化体(号3),并进一步通过基本上根据如1.6和2.3中描述的方法分析培养上清中的BSSL酶活性的产生。如表1所示,GS115[pARC 5797](号3)的培养上清含有BSSL酶活性,并直至诱导后72小时,其含量逐步增加。4.3.GS115[pARC 5797]转化体(号3)的培养上清的SDS-PAGE和蛋白质印迹分析
如节1.7和2.4描述的将在如节4.2描述的不同时间点收集的培养上清进行SDS-PAGE和蛋白质印迹分析。从SDS-PAGE图谱估测占全部细胞外蛋白75-80%的为BSSL-C,从SDS-PAGE估测的该蛋白的分子量为约66KDa,蛋白质印迹分析中,发现仅有66kDa周围的两条带(双联体)具有免疫反应性,从而证实了重组BSSL-C的表达。比较实施例,啤酒糖酵母中的BSSL的表达
曾尝试在啤酒糖酵母中表达BSSL。在啤酒糖酵母中BSSL分泌不佳,天然信号肽不能有效地起作用。此外,在啤酒糖酵母中天然信号肽没有从成熟蛋白质中切割。参考文献
Abouakil,N.Rogalska,E.,Bonicel,J.和Lombardo,D.(1988)生物化学和生物物理学报961,299-308。
Baba,T.,Downs,D.,Jackson,K.W.,Tang,J,和Wang,C-S(1991)生物化学30,500-510。
Blockberg,L.和Hernell,O,(1981)欧洲生物化学杂志,116,221-225。
Blckberg,L.,Angquist,K.A.和Hernell,O.(1987)FEBS Lett 217,37-41、
Cregg,J.M.等(1987)生物/技术5,479-485。
Ellis,S.B.等(1985)分子细胞生物学5,1111-1121。
Fredrikzon,B.,Hernell,O.,Blackberg,L.和Olivecrona,T.(1978)儿科研究12,1048-1052。
Hansson,L.,Blckberg,L.,Edlund,M.,Lundberg,L.,Stromqvist,M和Hernell,O.(1993)生物化学杂志268,26692-26698。
Hernell,O.和Olivecrona,T.(1974)生物化学生物物理学报369,234-244。
Hernell,O.,Blckberg,L.,和Olivecrona,T.(1989)中:婴儿胃肠学和营养教科书(Lebenthal,E.编)347-354。Raven Press,NY。
Hernell,O.和Blckberg,L.(1982)儿科研究16,882-885。
Hui,D.Y.和Kissel,J.A.(1990)FEBS Letters 276,131-134。
Kingsman等(1985)生物工程和遗传工程综述3,377-416。
Nilsson,J.,Blckberg,L.,Carlsson,P.,Enerbck,S.,Hernell,O.和Bjursell,G.(1990)欧洲生物化学杂志192,543-550。
Reue,K.,Zambaux,J,Wong,H.,Lee,G.,Leete,T.H.,Ronk,M.,Shively,J.E.Sternby,B.,Borgstrom,B.,Ameis,D.和Scholtz,M.C.(1991)脂质研究杂志32,267-276。
Wang,C-S和Hartsuck,J.A.(1993)生物化学生物物理进展1166,1-19。微生物保藏
转化到巴斯德毕赤酵母培养物的下面质粒已根据布达佩斯条约保藏在国立工业和海洋微生物保藏有限公司(NCIMB),Aberdeen,苏格兰,联合王国保藏日期为1995年5月2日。
表1毕赤酵母转化体培养上清中的酶活性
菌株[质粒] | NCIMB号 |
PPF-[pARC 5771] | 40721 |
GS115[pARC 5799] | 40723 |
GS115[pARC 5797] | 40722 |
诱导后的小时数 | 天然BSSL的酶活性(mg/L当量) | ||||
PPF-1[pARC 5771] | GS115[pARC 5799] | GS115[pARC 5797] | |||
No.39 | No.86 | No.9 | No.21 | No.3 | |
24 | 0.254 | 0.135 | 1.53 | 1.72 | 0.37 |
48 | 2.69 | 3.12 | 17.28 | 34.70 | 40.9 |
72 | 3.96 | 8.25 | 37.37 | 50.60 | 44.9 |
96 | 11.26 | 13.60 | 26.34 | 50.60 | 35.6 |
120 | 8.42 | 13.13 | 13.60 | 22.30 | 17.8 |
序列表(1)一般信息:(i)申请人:
(A)名称:ASTRA AB
(B)街道:Vāstra Mālarehamnen 9
(C)城市:Sōdertālje
(E)国家:瑞典
(F)邮编(ZIP):S-15185
(G)电话:+46-8-553 260 00
(H)电传:+46-8-553 288 20
(I)电报:19237astras(ii)发明名称:用于表达多肽的DNA序列(iii)序列数目:4(iv)计算机可读形式:
(A)介质类型:软盘
(B)计算机:IBM PC兼容
(C)操作系统:PC-DOS/MS-DOS
(D)软件:PatentIn Release#1.0,Version#1.30(EPC)(2)SEQ ID NO:1:信息:
(i)序列特征:
(A)长度:2428碱基对
(B)类型:核酸
(C)链型:双链
(D)拓扑学:线性
(ii)分子类型:cDNA to mRMA
(iii)假设:无
(iv)反义:无
(vi)初始来源:
(A)生物:人类
(F)组织类型:乳腺
(ix)特征:
(A)名称/键:CDS
(B)位置:82..2319
(D)其它信息:/产物=“胆汁盐刺激脂酶”(ix)特征:
(A)名称/键:外显子
(B)位置:985..1173(ix)特征:
(A)名称/键:外显子
(B)位置:1174..1377(ix)特征:
(A)名称/键:外显子
(B)位置:1378..1575(ix)特征:
(A)名称/键:外显子
(B)位置:1576..2415(ix)特征:
(A)名称/键:成熟肽
(B)位置:151..2316(ix)特征:
(A)名称/键:聚腺苷酸_信号
(B)位置:2397..2402(ix)特征:
(A)名称/键:重复区
(B)位置:1756..2283(ix)特征:
(A)名称/键:5′UTR
(B)位置:1..81(ix)特征:
(A)名称/键:重复_单元
(B)位置:1756..1788(ix)特征:
(A)名称/键:重复_单元
(B)位置:1789..1821(ix)特征:
(A)名称/键:重复_单元
(B)位置:1822..1854(ix)特征:
(A)名称/键:重复_单元
(B)位置:1855..1887(ix)特征:
(A)名称/键:重复_单元
(B)位置:1888..1920(ix)特征:
(A)名称/键:重复_单元
(B)位置:1921..1953(ix)特征:
(A)名称/键:重复_单元
(B)位置:1954..1986(ix)特征:
(A)名称/键:重复_单元
(B)位置:1987..2019(ix)特征:
(A)名称/键:重复_单元
(B)位置:2020..2052(ix)特征:
(A)名称/键:重复_单元
(B)位置:2053..2085(ix)特征:
(A)名称/键:重复_单元
(B)位置:2086..2118(ix)特征:
(A)名称/键:重复_单元
(B)位置:2119..2151(ix)特征:
(A)名称/键:重复_单元
(B)位置:2152..2184
(ix)特征:
(A)名称/键:重复_单元
(B)位置:2185..2217
(ix)特征:
(A)名称/键:重复_单元
(B)位置:2218..2250
(ix)特征:
(A)名称/键:重复_单元
(B)位置:2251..2283
(x)公开信息:
(A)作者:Nilsson,Jeanette
Blckberg,Lars
Carlsson,Peter
Enerbck,Sven
Hernell,Olle
Bjursell,Gunnar
(B)题目:人乳汁胆汁盐刺激脂酶的cDNA克隆以及与胰羧
酸酯水解酶相同的证据
(C)杂志:欧洲生物化学杂志
(D)卷号:192
(F)页数:543-550
(G)日期:9月-1990
(xi)序列描述:SEQ ID NO:1:信息:ACCTTCTGTA TCAGTTAAGT GTCAAGATGG AAGGAACAGC AGTTTTAAGA TAATGCAAAG 60AGTTTATTCA TCCAGAGGCT G ATG CTC ACC ATG GGG CGC CTG CAA CTG GTT 111
Met Leu Thr Met Gly Arg Leu Gln Leu Val
-23 -20 -15GTG TTG GGC CTC ACC TGC TGC TGG GCA GTG GCG AGT GCC GCG AAG CTG 159Val Leu Gly Leu Thr Cys Cys Trp Ala Val Ala Ser Ala Ala Lys Leu
-10 -5 1GGC GCC GTG TAC ACA GAA GGT GGG TTC GTG GAA GGC GTC AAT AAG AAG 207Gly Ala Val Tyr Thr Glu Gly Gly Phe Val Glu Gly Val Asn Lys Lys
5 10 15CTC GGC CTC CTG GGT GAC TCT GTG GAC ATC TTC AAG GGC ATC CCC TTC 255Leu Gly Leu Leu Gly Asp Ser Val Asp Ile Phe Lys Gly Ile Pro Phe20 25 30 35GCA GCT CCC ACC AAG GCC CTG GAA AAT CCT CAG CCA CAT CCT GGC TGG 303Ala Ala Pro Thr Lys Ala Leu Glu Asn Pro Gln Pro His Pro Gly Trp
40 45 50CAA GGG ACC CTG AAG GCC AAG AAC TTC AAG AAG AGA TGI CTG CAG GCC 351Gln Gly Thr Leu Lys Ala Lys Asn Phe Lys Lys Arg Cys Leu Gln Ala
55 60 65ACC ATC ACC CAG GAC AGC ACC TAC GGG GAT GAA GAC TGC CTG TAC CTC 399Thr Ile Thr Gln Asp Ser Thr Tyr Gly Asp Glu Asp Cys Leu Tyr Leu
70 75 80AAC ATT TGG GTG CCC CAG GGC AGG AAG CAA GTC TCC CGG GAC CTG CCC 447Asn Ile Trp Val Pro Gln Gly Arg Lys Gln Val Ser Arg Asp Leu Pro
85 90 95GTT ATG ATC TGG ATC TAT GGA GGC GCC TTC CTC ATG GGG TCC GGC CAT 495Val Met Ile Trp Ile Tyr Gly Gly Ala Phe Leu Met Gly Ser Gly His100 105 110 115GGG CCC AAC TTC CTC AAC AAC TAC CTG TAT GAC GGC GAG GAG ATC GCC 543Gly Ala Asn Phe Leu Asn Asn Tyr Leu Tyr Asp Gly Glu Glu Ile Ala
120 125 130ACA CGC GGA AAC GTC ATC GTG GTC ACC TTC AAC TAC CGT GTC GGC CCC 591Thr Arg Gly Asn Val Ile Val Val Thr Phe Asn Tyr Arg Val Gly Pro
135 140 145CTT GGG TTC CTC AGC ACT GGG GAC GCC AAT CTG CCA GGT AAC TAT GGC 639Leu Gly Phe Leu Ser Thr Gly Asp Ala Asn Leu Pro Gly Asn Tyr Gly
150 155 160CTT CGG GAT CAG CAC ATG GCC ATT GCT TGG GTG AAG AGG AAT ATC GCG 687Leu Arg Asp Gln His Met Ala Ile Ala Trp Val Lys Arg Asn Ile Ala
165 170 175GCC TTC GGG GGG GAC CCC AAC AAC ATC ACG CTC TTC GGG GAG TCT GCT 735Ala Phe Gly Gly Asp Pro Asn Asn Ile Thr Leu Phe Gly Glu Ser Ala180 185 190 195GGA GGT GCC AGC GTC TCT CTG CAG ACC CTC TCC CCC TAC AAC AAG GGC 783Gly Gly Ala Ser Val Ser Leu Gln Thr Leu Ser Pro Tyr Asn Lys Gly
200 205 210CTC ATC CGG CGA GCC ATC AGC CAG AGC GGC GTG GCC CTG AGT CCC TGG 831Leu Ile Arg Arg Ala Ile Ser Gln Ser Gly Val Ala Leu Ser Pro Trp
215 220 225GTC ATC CAG AAA AAC CCA CTC TTC TGG GCC AAA AAG GTG GCT GAG AAG 879Val Ile Gln Lys Asn Pro Leu Phe Trp Ala Lys Lys Val Ala Glu Lys
230 235 240GTG GGT TGC CCT GTG GGT GAT GCC GCC AGG ATG GCC CAG TGT CTG AAG 927Val Gly Cys Pro Val Gly Asp Ala Ala Arg Met Ala Gln Cys Leu Lys
245 250 255GTT ACT GAT CCC CGA GCC CTG ACG CTG GCC TAT AAG GTG CCG CTG GCA 975Val Thr Asp Pro Arg Ala Leu Thr Leu Ala Tyr Lys Val Pro Leu Ala260 265 270 275GGC CTG GAG TAC CCC ATG CTG CAC TAT GTG GGC TTC GTC CCT GTC ATT 1023Gly Leu Glu Tyr Pro Met Leu His Tyr Val Gly Phe Val Pro Val Ile
280 285 290GAT GGA GAC TTC ATC CCC GCT GAC CCG ATC AAC CTG TAC GCC AAC GCC 1071Asp Gly Asp Phe Ile Pro Ala Asp Pro Ile Asn Leu Tyr Ala Asn Ala
295 300 305GCC GAC ATC GAC TAT ATA GCA GGC ACC AAC AAC ATG GAC GGC CAC ATC 1119Ala Asp Ile Asp Tyr Ile Ala Gly Thr Asn Asn Met Asp Gly His Ile
310 315 320TTC GCC AGC ATC GAC ATG CCT GCC ATC AAC AAG GGC AAC AAG AAA GTC 1167Phe Ala Ser Ile Asp Met Pro Ala Ile Asn Lys Gly Asn Lys Lys Val
325 330 335ACG GAG GAG GAC TTC TAC AAG CTG GTC AGT GAG TTC ACA ATC ACC AAG 1215Thr Glu Glu Asp Phe Tyr Lys Leu Val Ser Glu Phe Thr Ile Thr Lys340 345 350 355GGG CTC AGA GGC GCC AAG ACG ACC TTT GAT GTC TAC ACC GAG TCC TGG 1263Gly Leu Arg Gly Ala Lys Thr Thr Phe Asp Val Tyr Thr Glu Ser Trp
360 365 370GCC CAG GAC CCA TCC CAG GAG AAT AAG AAG AAG ACT GTG GTG GAC TTT 1311Ala Gln Aap Pro Ser Gln Glu Asn Lys Lys Lys Thr Val Val Asp Phe
375 380 385GAG ACC GAT GTC CTC TTC CTG GTG CCC ACC GAG ATT GCC CTA GCC CAG 1359Glu Thr Asp Val Leu Phe Leu Val Pro Thr Glu Ile Ala Leu Ala Gln
390 395 400CAC AGA GCC AAT GCC AAG AGT GCC AAG ACC TAC GCC TAC CTG TTT TCC 1407His Arg Ala Asn Ala Lys Ser Ala Lys Thr Tyr Ala Tyr Leu Phe Ser
405 410 415CAT CCC TCT CGG ATG CCC GTC TAC CCC AAA TGG GTG GGG GCC GAC CAT 1455His Pro Ser Arg Met Pro Val Tyr Pro Lys Trp Val Gly Ala Asp His420 425 430 435GCA GAT GAC ATT CAG TAC GTT TTC GGG AAG CCC TTC GCC ACC CCC ACG 1503Ala Asp Asp Ile Gln Tyr Val Phe Gly Lys Pro Phe Ala Thr Pro Thr
440 445 450GGC TAC CGG CCC CAA GAC AGG ACA GTC TCT AAG GCC ATG ATC GCC TAC 1551Gly Tyr Arg Pro Gln Asp Arg Thr Val Ser Lys Ala Met Ile Ala Tyr
455 460 465TGG ACC AAC TTT GCC AAA ACA GGG GAC CCC AAC ATG GGC GAC TGG GCT 1599Trp Thr Asn Phe Ala Lys Thr Gly Asp Pro Asn Met Gly Asp Ser Ala
470 475 480GTG CCC ACA CAC TGG GAA CCC TAC ACT ACG GAA AAC AGC GGC TAC CTG 1647Val Pro Thr His Trp Glu Pro Tyr Thr Thr Glu Asn Ser Gly Tyr Leu
485 490 495GAG ATC ACC AAG AAG ATG GGC AGC AGC TCC ATG AAG CGG AGC CTG AGA 1695Glu Ile Thr Lys Lys Met Gly Ser Ser Ser Met Lys Arg Ser Leu Arg500 505 510 515ACC AAC TTC CTG CGC TAC TGG ACC CTC ACC TAT CTG GCG CTG CCC ACA 1743Thr Asn Phe Leu Arg Tyr Trp Thr Leu Thr Tyr Leu Ala Leu Pro Thr
520 525 530GTG ACC GAC CAG GAG GCC ACC CCT GTG CCC CCC ACA GGG GAC TCC GAG 1791Val Thr Asp Gln Glu Ala Thr Pro Val Pro Pro Thr Gly Asp Ser Glu
535 540 545GCC ACT CCC GTG CCC CCC ACG GGT GAC TCC GAG ACC GCC CCC GTG CCC 1839Ala Thr Pro Val Pro Pro Thr Gly Asp Ser Glu Thr Ala Pro Val Pro
550 555 560CCC ACG GGT GAC TCC GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC 1887Pro Thr Gly Asp Ser Gly Ala Pro Pro Val Pro Pro Thr Gly Asp Ser
565 570 575GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC GGG GCC CCC CCC GTG 1935Gly Ala Pro Pro Val Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro Val580 585 590 595CCG CCC ACG GGT GAC TCC GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC 1983Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro Val Pro Pro Thr Gly Asp
600 605 610TCC GGG GCC CCC CCC GTG CCG CCC ACG GGT GAC TCC GGG GCC CCC CCC 2031Ser Gly Ala Pro Pro Val Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro
615 620 625GTG CCG CCC ACG GGT GAC TCC GGC GCC CCC CCC GTG CCG CCC ACG GGT 2079Val Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro Val Pro Pro Thr Gly
630 635 640GAC GCC GGG CCC CCC CCC GTG CCG CCC ACG GGT GAC TCC GGC GCC CCC 2127Asp Ala Gly Pro Pro Pro Val Pro Pro Thr Gly Asp Ser Gly Ala Pro
645 650 655CCC GTG CCG CCC ACG GGT GAC TCC GGG GCC CCC CCC GTG ACC CCC ACG 2175Pro Val Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro Val Thr Pro Thr660 665 670 675GGT GAC TCC GAG ACC GCC CCC GTG CCG CCC ACG GGT GAC TCC GGG GCC 2223Gly Asp Ser Glu Thr Ala Pro Val Pro Pro Thr Gly Asp Ser Gly Ala
680 685 690CCC CCT GTG CCC CCC ACG GGT GAC TCT GAG GCT GCC CCT GTG CCC CCC 2271Pro Pro Val Pro Pro Thr Gly Asp Ser Glu Ala Ala Pro Val Pro Pro
695 700 705ACA GAT GAC TCC AAG GAA GCT CAG ATG CCT GCA GTC ATT AGG TTT TAG 2319Thr Asp Asp Ser Lys Glu Ala Gln Met Pro Ala Val Ile Arg Phe *
710 715 720CGTCCCATGA GCCTTGGTAT CAAGAGGCCA CAAGAGTGGG ACCCCAGGGG CTCCCCTCCC 2379ATCTTGAGCT CTTCCTGAAT AAAGCCTCAT ACCCCTAAAA AAAAAAAAA 2428(2)SEQ ID NO:2:信息:(i)序列特征:
(A)长度:746氨基酸
(B)类型:氨基酸
(D)拓扑学:线性(ii)分子类型:蛋白质(xi)序列描述:SEQ ID NO:2:信息:Met Leu Thr Met Gly Arg Leu Gln Leu Val Val Leu Gly Leu Thr Cys-23 -20 -15 -10Cys Trp Ala Val Ala Ser Ala Ala Lys Leu Gly Ala Val Tyr Thr Glu
-5 1 5Gly Gly Phe Val Glu Gly Val Asn Lys Lys Leu Gly Leu Leu Gly Asp
10 15 20 25Ser Val Asp Ile Phe Lys Gly Ile Pro Phe Ala Ala Pro Thr Lys Ala
30 35 40Leu Glu Asn Pro Gln Pro His Pro Gly Trp Gln Gly Thr Leu Lys Ala
45 50 55Lys Asn Phe Lys Lys Arg Cys Leu Gln Ala Tnr Ile Thr Gln Asp Ser
60 65 70Thr Tyr Gly Asp Glu Asp Cys Leu Tyr Leu Asn Ile Trp Val Pro Gln
75 80 85Gly Arg Lys Gln Val Ser Arg Asp Leu Pro Val Met Ile Trp Ile Tyr90 95 100 105Gly Gly Ala Phe Leu Met Gly Ser Gly His Gly Ala Asn Phe Leu Asn
110 115 120Asn Tyr Leu Tyr Asp Gly Glu Glu Ile Ala Thr Arg Gly Asn Val Ile
125 130 135Val Val Thr Phe Asn Tyr Arg Val Gly Pro Leu Gly Phe Leu Ser Thr
140 145 150Gly Asp Ala Asn Leu Pro Gly Asn Tyr Gly Leu Arg Asp Gln His Met
155 160 165Ala Ile Ala Trp Val Lys Arg Asn Ile Ala Ala Phe Gly Gly Asp Pro170 175 180 185Asn Asn Ile Thr Leu Phe Gly Glu Ser Ala Gly Gly Ala Ser Val Ser
190 195 200Leu Gln Thr Leu Ser Pro Tyr Asn Lys Gly Leu Ile Arg Arg Ala Ile
205 210 215Ser Gln Ser Gly Val Ala Leu Ser Pro Trp Val Ile Gln Lys Asn Pro
220 225 230Leu Phe Trp Ala Lys Lys Val Ala Glu Lys Val Gly Cys Pro Val Gly
235 240 245Asp Ala Ala Arg Met Ala Gln Cys Leu Lys Val Thr Asp Pro Arg Ala250 255 260 265Leu Thr Leu Ala Tyr Lys Val Pro Leu Ala Gly Leu Glu Tyr Pro Met
270 275 280Leu His Tyr Val Gly Phe Val Pro Val Ile Asp Gly Asp Phe Ile Pro
285 290 295Ala Asp Pro Ile Asn Leu Tyr Ala Asn Ala Ala Asp Ile Asp Tyr Ile
300 305 310Ala Gly Thr Asn Asn Met Asp Gly His Ile Phe Ala Ser Ile Asp Met
315 320 325Pro Ala Ile Asn Lys Gly Asn Lys Lys Val Thr Glu Glu Asp Phe Tyr330 335 340 345Lys Leu Val Ser Glu Phe Thr Ile Thr Lys Gly Leu Arg Gly Ala Lys
350 355 360Thr Thr Phe Asp Val Tyr Thr Glu Ser Trp Ala Gln Asp Pro Ser Gln
365 370 375Glu Asn Lys Lys Lys Thr Val Val Asp Phe Glu Thr Asp Val Leu Phe
380 385 390Leu Val Pro Thr Glu Ile Ala Leu Ala Gln His Arg ALa Asn Ala Lys
395 400 405Ser Ala Lys Thr Tyr Ala Tyr Leu Phe Ser His Pro Ser Arg Met Pro410 415 420 425Val Tyr Pro Lys Trp Val Gly Ala Asp His Ala Asp Asp Ile Gln Tyr
430 435 440Val Phe Gly Lys Pro Phe Ala Thr Pro Thr Gly Tyr Arg Pro Gln Asp
445 450 455Arg Thr Val Ser Lys Ala Met Ile Ala Tyr Trp Thr Asn Phe Ala Lys
460 465 470Thr Gly Asp Pro Asn Met Gly Asp Ser Ala Val Pro Thr His Trp Glu
475 480 485Pro Tyr Thr Thr Glu Asn Ser Gly Tyr Leu Glu Ile Thr Lys Lys Met490 495 500 505Gly Ser Ser Ser Met Lys Arg Ser Leu Arg Thr Asn Phe Leu Arg Tyr
510 515 520Trp Thr Leu Thr Tyr Leu Ala Leu Pro Thr Val Thr Asp Gln Glu Ala
525 530 535Thr Pro Val Pro Pro Thr Gly Asp Ser Glu Ala Thr Pro Val Pro Pro
540 545 550Thr Gly Asp Ser Glu Thr Ala Pro Val Pro Pro Thr Gly Asp Ser Gly
555 560 565Ala Pro Pro Val Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro Val Pro570 575 580 585Pro Thr Gly Asp Ser Gly Ala Pro Pro Val Pro Pro Thr Gly Asp Ser
590 595 600Gly Ala Pro Pro Val Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro Val
605 610 615Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro Val Pro Pro Thr Gly Asp
620 625 630Ser Gly Ala Pro Pro Val Pro Pro Thr Gly Asp Ala Gly Pro Pro Pro
635 640 645Val Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro Val Pro Pro Thr Gly650 655 660 665Asp Ser Gly Ala Pro Pro Val Thr Pro Thr Gly Asp Ser Glu Thr Ala
670 675 680Pro Val Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro Val Pro Pro Thr
685 690 695Gly Asp Ser Glu Ala Ala Pro Val Pro Pro Thr Asp Asp Ser Lys Glu
700 705 710Ala Gln Met Pro Ala Val Ile Arg Phe *
715 720(2) SEQ ID NO:3:信息:
(i)序列特征:
(A)长度:722氨基酸
(B)类型:氨基酸
(C)链型:
(D)拓扑学:线性
(ii)分子类型:蛋白质
(iii)假设:无
(vi)初始来源:
(A)生物:人类
(F)组织类型:乳腺
(xi)序列描述:SEQ ID NO:3:Ala Lys Leu Gly Ala Val Tyr Thr Glu Gly Gly Phe Val Glu Gly Val1 5 10 15Asn Lys Lys Leu Gly Leu Leu Gly Asp Ser Val Asp Ile Phe Lys Gly
20 25 30Ile Pro Phe Ala Ala Pro Thr Lys Ala Leu Glu Asn Pro Gln Pro His
35 40 45Pro Gly Trp Gln Gly Thr Leu Lys Ala Lys Asn Phe Lys Lys Arg Cys
50 55 60Leu Gln Ala Thr Ile Thr Gln Asp Ser Thr Tyr Gly Asp Glu Asp Cys65 70 75 80Leu Tyr Leu Asn Ile Trp Val Pro Gln Gly Arg Lys Gln Val Ser Arg
85 90 95Asp Leu Pro Val Met Ile Trp Ile Tyr Gly Gly Ala Phe Leu Met Gly
100 105 110Ser Gly His Gly Ala Asn Phe Leu Asn Asn Tyr Leu Tyr Asp Gly Glu
115 120 125Glu Ile Ala Thr Arg Gly Asn Val Ile Val Val Thr Phe Asn Tyr Arg
130 135 140Val Gly Pro Leu Gly Phe Leu Ser Thr Gly Asp Ala Asn Leu Pro Gly145 150 155 160Asn Tyr Gly Leu Arg Asp Gln His Met Ala Ile Ala Trp Val Lys Arg
165 170 175Asn Ile Ala Ala Phe Gly Gly Asp Pro Asn Asn Ile Thr Leu Phe Gly
180 185 190Glu Ser Ala Gly Gly Ala Ser Val Ser Leu Gln Thr Leu Ser Pro Tyr
195 200 205Asn Lys Gly Leu Ile Arg Arg Ala Ile Ser Gln Ser Gly Val Ala Leu
210 215 220Ser Pro Trp Val Ile Gln Lys Asn Pro Leu Phe Trp Ala Lys Lys Val225 230 235 240Ala Glu Lys Val Gly Cys Pro Val Gly Asp Ala Ala Arg Met Ala Gln
245 250 255Cys Leu Lys Val Thr Asp Pro Arg Ala Leu Thr Leu Ala Tyr Lys Val
260 265 270Pro Leu Ala Gly Leu Glu Tyr Pro Met Leu His Tyr Val Gly Phe Val
275 280 285Pro Val Ile Asp Gly Asp Phe Ile Pro Ala Asp Pro Ile Asn Leu Tyr
290 295 300Ala Asn Ala Ala Asp Ile Asp Tyr Ile Ala Gly Thr Asn Asn Met Asp305 310 315 320Gly His Ile Phe Ala Ser Ile Asp Met Pro Ala Ile Asn Lys Gly Asn
325 330 335Lys Lys Val Thr Glu Glu Asp Phe Tyr Lys Leu Val Ser Glu Phe Thr
340 345 350Ile Thr Lys Gly Leu Arg Gly Ala Lys Thr Thr Phe Asp Val Tyr Thr
355 360 365Glu Ser Trp Ala Gln Aep Pro Ser Gln Glu Asn Lys Lys Lys Thr Val
370 375 380Val Asp Phe Glu Thr Asp Val Leu Phe Leu Val Pro Thr Glu Ile Ala385 390 395 400Leu Ala Gln His Arg Ala Asn Ala Lys Ser Ala Lys Thr Tyr Ala Tyr
405 410 415Leu Phe Ser His Pro Ser Arg Met Pro Val Tyr Pro Lys Trp Val Gly
420 425 430Ala Asp His Ala Asp Asp Ile Gln Tyr Val Phe Gly Lys Pro Phe Ala
435 440 445Thr Pro Thr Gly Tyr Arg Pro Gln Asp Arg Thr Val Ser Lys Ala Met
450 455 460Ile Ala Tyr Trp Thr Asn Phe Ala Lys Thr Gly Asp Pro Asn Met Gly465 470 475 480Asp Ser Ala Val Pro Thr His Trp Glu Pro Tyr Thr Thr Glu Asn Ser
485 490 495Gly Tyr Leu Glu Ile Thr Lys Lys Met Gly Ser Ser Ser Met Lys Arg
500 505 510Ser Leu Arg Thr Asn Phe Leu Arg Tyr Trp Thr Leu Thr Tyr Leu Ala
515 520 525Leu Prc Thr Val Thr Asp Gln Glu Ala Thr Pro Val Pro Pro Thr Gly
530 535 540Asp Ser Glu Ala Thr Pro Val Pro Pro Thr Gly Asp Ser Glu Thr Ala545 550 555 560Pro Val Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro Val Pro Pro Thr
565 570 575Gly Asp Ser Gly Ala Pro Pro Val Pro Pro Thr Gly Asp Ser Gly Ala
580 585 590
Pro Pro Val Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro Val Pro Pro
595 600 605
Thr Gly Asp Ser Gly Ala Pro Pro Val Pro Pro Thr Gly Asp Ser Gly
610 615 620
Ala Pro Pro Val Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro Val Pro
625 630 635 640
Pro Thr Gly Asp Ala Gly Pro Pro Pro Val Pro Pro Thr Gly Asp Ser
645 650 655
Gly Ala Pro Pro Val Pro Pro Thr Gly Asp Ser Gly Ala Pro Pro Val
660 665 670
Thr Pro Thr Gly Asp Ser Glu Thr Ala Pro Val Pro Pro Thr Gly Asp
675 680 685
Ser Gly Ala Pro Pro Val Pro Pro Thr Gly Asp Ser Glu Ala Ala Pro
690 695 700
Val Pro Pro Thr Asp Asp Ser Lys Glu Ala Gln Met Pro Ala Val Ile
705 710 715 720
Arg Phe(2) SEQ ID NO:4:信息:
(i)序列特征:
(A)长度:568氨基酸
(B)类型:氨基酸
(C)链型:
(D)拓扑学:线性
(ii)分子类型:蛋白质
(iii)假设:无
(vi)初始来源:
(A)生物:人类
(F)组织类型:乳腺
(ix)特征:
(A)名称/键:肽
(B)位置:1..568
(D)其它信息:/标记=变异体_C
(x)公开信息:
(A)作者:Hansson,Lennart
Blackberg,Lars
EdlundMichael
Lundberg,Lennart
Stromqvist,Mats
Hernell,Olle
(B)题目:重组人乳汁胆汁盐刺激脂酶
(C)杂志:生物化学杂志
(D)卷号:268
(E)出版:35
(F)页数:2669226698
(G)日期:1993.12.15(xi)序列描述:SEQ ID NO:4:Ala Lys Leu Gly Ala Val Tyr Thr Glu Gly Gly Phe Val Glu Gly Val1 5 10 15Asn Lys Lys Leu Gly Leu Leu Gly Asp Ser Val Asp Ile Phe Lys Gly
20 25 30Ile Pro Phe Ala Ala Pro Thr Lys Ala Leu Glu Asn Pro Gln Pro His
35 40 45Pro Gly Trp Gln Gly Thr Leu Lys Ala Lys Asn Phe Lys Lys Arg Cys
50 55 60Leu Gln Ala Thr Ile Thr Gln Asp Ser Thr Tyr Gly Asp Glu Asp Cys65 70 75 80Leu Tyr Leu Asn Ile Trp Val Pro Gln Gly Arg Lys Gln Val Ser Arg
85 90 95Asp Leu Pro Val Met Ile Trp Ile Tyr Gly Gly Ala Phe Leu Met Gly
100 105 110Ser Gly His Gly Ala Asn Phe Leu Asn Asn Tyr Leu Tyr Asp Gly Glu
115 120 125Glu Ile Ala Thr Arg GLy Asn Val Ile Val Val Thr Phe Asn Thr Arg
130 135 140Val Gly Pro Leu Gly Phe Leu Ser Thr Gly Asp Ala Asn Leu Pro Gly145 150 155 160Asn Tyr Gly Leu Arg Asp Gln His Met Ala Ile Ala Trp Val Lys Arg
165 170 175Asn Ile Ala Ala Phe Gly Gly Asp Pro Asn Asn Ile Thr Leu Phe Gly
180 185 190Glu Ser Ala Gly Gly Ala Ser Val Ser Leu Gln Thr Leu Ser Pro Tyr
195 200 205Asn Lys Gly Leu Ile Arg Arg Ala Ile Ser Gln Ser Gly Val Ala Leu
210 215 220Ser Pro Trp Val Ile Gln Lys Asn Pro Leu Phe Trp Ala Lys Lys Val225 230 235 240Ala Glu Lys Val Gly Cys Pro Val Gly Asp Ala Ala Arg Met Ala Gln
245 250 255Cys Leu Lys Val Thr Asp Pro Arg Ala Leu Thr Leu Ala Tyr Lys Val
260 265 270Pro Leu Ala Gly Leu Glu Tyr Pro Met Leu His Tyr Val Gly Phe Val
275 280 285Pro Val Ile Asp Gly Asp Phe Ile Pro Ala Asp Pro Ile Asn Leu Tyr
290 295 300Ala Asn Ala Ala Asp Ile Asp Tyr Ile Ala Gly Thr Asn Asn Met Asp305 310 315 320Gly His Ile Phe Ala Ser Ile Asp Met Pro Ala Ile Asn Lys Gly Asn
325 330 335Lys Lys Val Thr Glu Glu Asp Phe Tyr Lys Leu Val Ser Glu Phe Thr
340 345 350Ile Thr Lys Gly Leu Arg Gly Ala Lys Thr Thr Phe Asp Val Tyr Thr
355 360 365Glu Ser Trp Ala Gln Asp Pro Ser Gln Glu Asn Lys Lys Lys Thr Val
370 375 380Val Asp Phe Glu Thr Asp Val Leu Phe Leu Val Pro Thr Glu Ile Ala385 390 395 400Leu Ala Gln His Arg Ala Asn Ala Lys Ser Ala Lys Thr Tyr Ala Tyr
405 410 415Leu Phe Ser His Pro Ser Arg Met Pro Val Tyr Pro Lys Trp Val Gly
420 425 430Ala Asp His Ala Asp Asp Ile Gln Tyr Val Phe Gly Lys Pro Phe Ala
435 440 445Thr Pro Thr Gly Tyr Arg Pro Gln Asp Arg Thr Val Ser Lys Ala Met
450 455 460Ile Ala Tyr Trp Thr Asn Phe Ala Lys Thr Gly Asp Pro Asn Met Gly465 470 475 480Asp Ser Ala Val Pro Thr His Trp Glu Pro Tyr Thr Thr Glu Asn Ser
485 490 495Gly Tyr Leu Glu Ile Thr Lys Lys Met Gly Ser Ser Ser Met Lys Arg
500 505 510Ser Leu Arg Thr Asn Phe Leu Arg Tyr Trp Thr Leu Thr Tyr Leu Ala
515 520 525Leu Pro Thr Val Thr Asp Gln Gly Ala Pro Pro Val Pro Pro Thr Gly
530 535 540Asp Ser Gly Ala Pro Pro Val Pro Pro Thr Gly Asp Ser Lys Glu Ala545 550 555 560Gln Met Pro Ala Val Ile Arg Phe
565
Claims (14)
1.一种DNA分子,包括
(a)编码为人BSSL或其生物活性变异体的多肽的区域;
(b)与所述多肽编码区的5′末端相连的,编码能操纵所述多肽从用所述DNA分子转化的巴斯德毕赤酵母细胞分泌的信号肽的区域;
(c)可操作性地与(a)和(b)中定义的所述编码区相连的巴斯德毕赤酵母的甲醇氧化酶启动子或功能相同的启动子。
2.根据权利要求1的DNA分子,其中所述信号肽与序列表中SEQ IDNO:2的氨基酸-20至-1所示的氨基酸序列相同或基本类似。
3.根据权利要求1的DNA分子,其中所述信号肽包含啤酒糖酵母转化酶信号肽。
4.根据权利要求1-3任一项的编码人BSSL生物活性变异体的DNA分子,其中缺失至少一个11个氨基酸的重复单元,所述重复单元示于SEQ ID NO:1中。
5.根据权利要求1-4任一项的DNA分子,其编码具有BSSL活性并具有与SEQ ID NO:3或SEQ ID NO:4的序列存在至少95%同源性的氨基酸序列的多肽。
6.根据权利要求1-5任一项的DNA分子,其编码具有SEQ ID NO:3或SEQ ID NO:4的氨基酸序列的多肽。
7.一种载体,包含根据权利要求1-6任一项的DNA分子。
8.根据权利要求7的可复制表达载体,它能介导巴斯德毕赤酵母细胞中人BSSL或其生物活性变异体的表达。
9.根据权利要求8的载体,其为质粒载体pARC 5771(NCIMB40721),pARC 5799(NCIMB,40723)或pARC 5797(NCIMB40722)。
10.用根据权利要求7-9任一项的载体转化的毕赤酵母属的宿主细胞。
11.根据权利要求10的宿主细胞,为巴斯德毕赤酵母细胞。
12.根据权利要求11的宿主细胞,巴斯德毕赤酵母细胞GS115株。
13.根据权利要求12的宿主细胞,为PPF-1[pARC 5771](NCIMB40721),GS115[pARC 5799](NCIMB 40723)或GS115[pARC 5797](NCIMB 40722)。
14.一种制备人BSSL或其生物活性变异体的多肽的方法,包括在使所述多肽分泌到培养基中的条件下培养根据权利要求10-13任一项的宿主细胞,并从培养基中回收所述多肽。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE95019394 | 1995-05-24 | ||
SE9501939A SE9501939D0 (sv) | 1995-05-24 | 1995-05-24 | DNA molecules for expression of polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1185812A true CN1185812A (zh) | 1998-06-24 |
Family
ID=20398427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN96194083A Pending CN1185812A (zh) | 1995-05-24 | 1996-03-12 | 表达胆汁盐刺激脂酶(bssl)的dna分子 |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0832257A1 (zh) |
JP (1) | JP2000510683A (zh) |
KR (1) | KR19980703238A (zh) |
CN (1) | CN1185812A (zh) |
AU (1) | AU5165696A (zh) |
CZ (1) | CZ297397A3 (zh) |
EE (1) | EE9700321A (zh) |
HU (1) | HUP9802388A3 (zh) |
IL (1) | IL118335A0 (zh) |
PL (1) | PL322848A1 (zh) |
RU (1) | RU2157847C2 (zh) |
SE (1) | SE9501939D0 (zh) |
TR (1) | TR199701010T1 (zh) |
TW (1) | TW434314B (zh) |
WO (1) | WO1996037622A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101415824B (zh) * | 2006-04-12 | 2012-02-29 | 韩国生命工学研究院 | 获自毕赤酵母的自动诱导型磷酸钠协同转运体启动子和利用该启动子制造重组蛋白的方法 |
CN114096275A (zh) * | 2019-07-12 | 2022-02-25 | 利普姆股份制有限公司 | 新型bssl抗体 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001081368A2 (en) * | 2000-04-21 | 2001-11-01 | Monsanto Technology Llc | Blood-pressure reducing polypeptides containing vpp derived from microorganisms |
CN103952386A (zh) * | 2014-03-31 | 2014-07-30 | 四川农业大学 | 利用毕赤酵母高效分泌表达重组猪胰腺脂肪酶ppl的方法 |
RU2697218C1 (ru) * | 2018-07-11 | 2019-08-13 | федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (национальный исследовательский университет)" | Использование сигнальных пептидов митохондриальной локализации для увеличения уровня гетерологической экспрессии белков в P.pastoris и S.cerevisiae |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05184352A (ja) * | 1990-01-16 | 1993-07-27 | Centro De Ing Genetica Y Biotecnol | ピヒア パストリス(Pichia pastoris)酵母中での異種遺伝子の発現方法、発現ベクターおよび形質転換微生物 |
IS4130A (is) * | 1993-03-01 | 1994-09-02 | Ab Astra | Ný fjölpeptíð |
-
1995
- 1995-05-24 SE SE9501939A patent/SE9501939D0/xx unknown
-
1996
- 1996-03-12 TR TR97/01010T patent/TR199701010T1/xx unknown
- 1996-03-12 KR KR1019970706642A patent/KR19980703238A/ko not_active Application Discontinuation
- 1996-03-12 EE EE9700321A patent/EE9700321A/xx unknown
- 1996-03-12 WO PCT/SE1996/000318 patent/WO1996037622A1/en not_active Application Discontinuation
- 1996-03-12 HU HU9802388A patent/HUP9802388A3/hu unknown
- 1996-03-12 CN CN96194083A patent/CN1185812A/zh active Pending
- 1996-03-12 CZ CZ972973A patent/CZ297397A3/cs unknown
- 1996-03-12 RU RU97117367/13A patent/RU2157847C2/ru not_active IP Right Cessation
- 1996-03-12 AU AU51656/96A patent/AU5165696A/en not_active Abandoned
- 1996-03-12 PL PL96322848A patent/PL322848A1/xx unknown
- 1996-03-12 JP JP08535592A patent/JP2000510683A/ja not_active Abandoned
- 1996-03-12 EP EP96908415A patent/EP0832257A1/en not_active Withdrawn
- 1996-04-10 TW TW085104253A patent/TW434314B/zh active
- 1996-05-20 IL IL11833596A patent/IL118335A0/xx unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101415824B (zh) * | 2006-04-12 | 2012-02-29 | 韩国生命工学研究院 | 获自毕赤酵母的自动诱导型磷酸钠协同转运体启动子和利用该启动子制造重组蛋白的方法 |
CN114096275A (zh) * | 2019-07-12 | 2022-02-25 | 利普姆股份制有限公司 | 新型bssl抗体 |
Also Published As
Publication number | Publication date |
---|---|
TR199701010T1 (xx) | 1998-01-21 |
TW434314B (en) | 2001-05-16 |
HUP9802388A2 (hu) | 1999-02-01 |
EE9700321A (et) | 1998-06-15 |
IL118335A0 (en) | 1996-09-12 |
EP0832257A1 (en) | 1998-04-01 |
HUP9802388A3 (en) | 2000-10-30 |
SE9501939D0 (sv) | 1995-05-24 |
CZ297397A3 (cs) | 1998-03-18 |
RU2157847C2 (ru) | 2000-10-20 |
WO1996037622A1 (en) | 1996-11-28 |
KR19980703238A (ko) | 1998-10-15 |
PL322848A1 (en) | 1998-02-16 |
JP2000510683A (ja) | 2000-08-22 |
AU5165696A (en) | 1996-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1151264C (zh) | 农杆菌介导的霉菌特别是属于曲霉菌属的霉菌的转化 | |
CN1230537C (zh) | 来自曲霉属融合产物中经加工的重组乳铁蛋白和乳铁蛋白多肽片断的表达 | |
CN1253574C (zh) | 来自米曲霉的areA基因和其中areA基因已被修饰的真菌 | |
CN1262639C (zh) | 新的宿主细胞和生产蛋白质的方法 | |
CN1219064C (zh) | 植物脂肪酸去饱和酶启动子 | |
CN1171993C (zh) | 编码对n-乙酰基-l-膦丝菌素具有特异性的氨基酸脱乙酰酶的新基因,其分离和应用 | |
CN1151258C (zh) | 通过内源基因活化制备促红细胞生成素 | |
CN1062169A (zh) | 巴斯德毕赤酵母酸性磷酸酶基因 | |
CN1117151C (zh) | 真菌中的核黄素生物合成 | |
CN1144874C (zh) | 具酶活性的重组羧肽酶b的生产 | |
CN1086262A (zh) | 新的dna序列 | |
CN1011243B (zh) | 酵母菌异源基因表达的调节区 | |
CN1284129A (zh) | 热稳定的葡糖淀粉酶 | |
CN1225550C (zh) | 表达降低水平的金属蛋白酶的宿主细胞和在蛋白质产生中使用该宿主细胞的方法 | |
CN1114355A (zh) | Dna扩增 | |
CN1160465C (zh) | 其中areA、pepC和/或pepE基因已被灭活的真菌 | |
CN1145953A (zh) | 编码具有δ-5,7甾醇,δ-7还原酶活性的蛋白质的DNA序列和该蛋白质及生产方法,转化酵母菌株,用途 | |
CN1223663A (zh) | 转录因子 | |
CN1185812A (zh) | 表达胆汁盐刺激脂酶(bssl)的dna分子 | |
CN1086737C (zh) | 超热稳定蛋白酶基因 | |
CN1125181C (zh) | 在酵母细胞中表达n-末端延伸蛋白质的载体 | |
CN1391612A (zh) | 来自嗜热棒状杆菌的氨基酸生物合成途径的抗热酶的基因 | |
CN1213402A (zh) | 表层蛋白的重组表达 | |
CN1219200A (zh) | 谷氨酸脱氢酶、β-N-乙酰氨基己糖苷酶和γ-肌动蛋白基因的启动子以及它们在丝状真菌表达,分泌和反义系统中的应用 | |
CN100339479C (zh) | 参与油菜素类固醇合成的基因 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |